title: Bradykinin antagonists: new opportunities.
abstract: The pro-inflammatory, pain producing, and cardiovascular effects of bradykinin B2 receptor activation are well characterized. Bradykinin B1 receptors also produce inflammation and pain. Therefore, antagonists are expected to be anti-inflammatory/analgesic drugs. Other exploitable clinical opportunities may exist. The newly discovered non-peptide B2 receptor antagonists and the equivalent B1 receptor pharmacological agents, which are in the pipeline, are suitable preclinical tools to properly evaluate potential utilities.
authors.affiliation: Merck Research Laboratories, West Point, PA 19486, USA. mark_bock@merck.com
authors.forename: M G
authors.initials: MG
authors.lastname: Bock
authors.forename: J
authors.initials: J
authors.lastname: Longmore
mesh_terms: D001920:Bradykinin / Q000037:antagonists & inhibitors*; D065168:Bradykinin Receptor Antagonists; D004355:Drug Stability; D005544:Forecasting; D006801:Humans; D015394:Molecular Structure; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D065168:Bradykinin Receptor Antagonists; D009842:Oligopeptides; D001920:Bradykinin